Sun Pharma screeches to the psoriasis finish line with FDA OK of Ilumya. Too bad rivals J&J and others beat them to it
In the crowded race to launch new therapies for psoriasis, India’s largest drugmaker Sun Pharma hustled to the finish line Thursday with FDA approval of tildrakizumab. Unfortunately for Sun, several other drugmakers were already there waiting.
The company’s biologic, which is now branded as Ilumya, was first in-licensed from Merck back in 2014 for $80 million. The med, delivered through subcutaneous injection, was already in Phase III trials at the time of the deal, and Merck handed all regulatory and launch responsibilities over to Sun.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.